Systemic lupus erythematosus (SLE), commonly called lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy tissues. It can affect the skin, joints, blood, kidneys, brain, and other organs. Standard treatments—including steroids, immunosuppressants, and biologic drugs—can control inflammation for many people, but some patients continue to relapse or develop organ damage despite treatment. A new 2026 review explores an emerging approach that may someday change the goal of lupus care: using engineered immune cells to create a longer-lasting “reset” of the immune system.
The therapy is called CAR-T cell therapy, short for chimeric antigen receptor T-cell therapy. It was first developed to treat certain blood cancers. In CAR-T treatment, doctors collect a patient’s T cells—an important type of immune cell—and genetically modify them in a laboratory. The modified cells are programmed with a receptor that helps them recognize and destroy specific harmful cells. After the engineered cells are infused back into the patient, they seek out their target.
Why target B cells?
In lupus, B cells play a major role in disease activity. They produce autoantibodies, including anti-double-stranded DNA antibodies, that can form immune complexes and contribute to inflammation and tissue injury. The kidneys are especially vulnerable, which is why uncontrolled lupus can lead to lupus nephritis.
Most CAR-T approaches for lupus target CD19, a marker found on many B cells. Other strategies target BCMA, a marker associated with antibody-producing plasma cells, or both CD19 and BCMA at the same time. The goal is to remove the abnormal B-cell populations that help sustain lupus and then allow the immune system to rebuild in a less autoreactive way.
This differs from standard B-cell depletion treatments. Conventional therapies may reduce B cells but can leave behind tissue-resident B cells or long-lived plasma cells that continue producing damaging antibodies. CAR-T cells may produce deeper depletion across multiple B-cell compartments, although the relative benefit and risks of each targeting strategy still need confirmation in larger studies
Early studies are promising
The review summarizes small clinical studies in people with difficult-to-treat lupus. In early reports, CD19-directed CAR-T therapy led to rapid B-cell depletion, reductions in disease activity, improvements in kidney-related measures such as proteinuria, and normalization of some lupus blood markers. In several cases, B cells returned after a few months, but they were initially dominated by immature, naïve B cells rather than the memory B-cell populations associated with prior autoimmune activity.That observation has led researchers to describe CAR-T therapy as a possible form of immune reprogramming. Instead of continuously suppressing an abnormal immune system, the treatment may eliminate much of the existing disease-associated B-cell network and allow a new B-cell repertoire to develop. Some patients in early studies maintained medication-free remission after immune recovery, but these findings come from small, mostly uncontrolled cohorts and cannot yet prove that CAR-T creates a durable cure.Dual-target CAR-T therapies, which target both CD19 and BCMA, may offer a more comprehensive approach by reaching both earlier B cells and antibody-producing plasma cells. The review describes early evidence of deep immune-cell depletion, improvements in lupus nephritis pathology, and prolonged drug-free remission in some refractory cases
Progress comes with risks
CAR-T therapy is intensive. Patients typically need lymphodepleting chemotherapy before infusion, and the treatment can cause cytokine release syndrome (CRS), an inflammatory reaction that may range from flu-like symptoms to severe illness. B-cell depletion can also lower immunoglobulin levels, raising infection concerns. The review notes that approximately half of patients may develop hypogammaglobulinemia, although immune function and vaccine-related antibodies may recover over time.
Researchers are also testing potentially more accessible versions, including donor-derived “off-the-shelf” CAR-T cells, CAR-natural killer cells, and CAR-regulatory T cells designed to calm autoimmunity without broadly eliminating B cells. These approaches remain early in development.
